GLP-1 Medications for Weight Loss Now Available!
                    
                    
                 
             
            
                                            
                The city of Port Orange, Florida, currently has 3 active clinical trials seeking participants for Weight Loss research studies. 
            
                        
                                                                    
    
        
            
                
                                    VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
                                
            
            
         
        
     
    
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight             
        
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight 
Read Less
            
         
    
        
            
            
            
                Trial Updated:
                08/12/2025
             
         
        
            Locations: Viking Clinical Site #2011, Port Orange, Florida         
        
                            Viking Clinical Site #2011, Port Orange, Florida
                     
        
            
        
     
                             
    
        
            
                
                                    VK2735 for Weight Management Phase 3
                                
            
            
         
        
     
    
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.             
        
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes. 
Read Less
            
         
    
        
            
            
            
                Trial Updated:
                08/12/2025
             
         
        
            Locations: Viking Clinical Site #1011, Port Orange, Florida         
        
                            Viking Clinical Site #1011, Port Orange, Florida
                     
        
            
        
     
                             
    
        
            
                
                                    VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
                                
            
            
         
        
     
    
        
            
                This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
VK2735 or matched placebo will be administered once daily.             
        
        
            
                This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
VK2735 or matched placebo will be administered once daily. 
Read Less
            
         
    
        
            
            
            
                Trial Updated:
                02/19/2025
             
         
        
            Locations: Viking Clinical Site #102, Port Orange, Florida         
        
                            Viking Clinical Site #102, Port Orange, Florida